Verismo will initiate a Phase I trial of its CAR T therapy SynKIR-310 for B-cell non-Hodgkin lymphoma. According to GlobalData, there will be over 1.8 billion cases of B-cell NHL in 2027 globally. Credit: Ground Picture via Shutterstock.

The US Food and Drug Administration (FDA) has cleared Verismo Therapeutics’ investigational new drug (IND) application to advance its CAR-T therapy SynKIR-310 into a Phase I clinical trial.  

The Phase I CELESTIAL-301 trial will enrol patients with relapsed or refractory B-cell non-Hodgkin lymphomas (B-cell NHL), whether they have had prior CAR-T therapy or not. Verismo plans to initiate the CELESTIAL-301 clinical trial in the second half of 2024. 

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

CAR-T therapies have proven to be successful in the management of select haematologic malignancies. However, many patients relapse due to a lack of long-term T cell effector function.  

The therapeutic avenues available post-relapse after CAR-T therapy are limited, underscoring the need for new therapies that can augment current survival outcomes.  

Verismo’s KIR-CAR platform uses natural killer (NK) cell-derived KIR and DAP12 split signalling to activate and stimulate the immune system, helping CAR-T cells stay active for longer and fight against both solid tumours and blood cancers. SynKIR-19 targets and destroys cells with CD19, a protein found in B lymphocytes. It binds to overexpressed tumour antigens, activating T cells and triggering targeted killing of tumour cells.  

The cell therapy startup spun out of the University of Pennsylvania in 2020. It has since raised $50m, generating $17m in a second pre-Series A round co-led by DongKoo Bio, HLB Innovation and HLB in July 2023. Verismo established a research and development centre at CIC Philadelphia in 2022 to advance its KIR-CAR platform. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Verismo’s lead candidate SynKIR-110 is under investigation in the Phase I STAR-101 clinical trial (NCT05568680) for mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma. The study plans to enrol 42 subjects receiving single-dose intravenous (IV) administration, with dosing escalated using a 3 + 3 design. Additional subjects will be enrolled at the maximum tolerated dose to further evaluate safety and potential activity. 

According to a report on GlobalData’s Pharma Intelligence Center, the number of diagnosed prevalent cases of B-cell NHL will exceed 1.8 billion in 2027 globally.  

GlobalData is the parent company of Pharmaceutical Technology. 

In the announcement accompanying the IND, Verismo’s chief scientific officer Laura Johnson said: “The SynKIR-310 technology is designed to enhance the anti-tumour activity and extend the efficacy of T cells. This could potentially improve persistence and prevent early disease relapse in patients with aggressive lymphomas. SynKIR-310 could be especially beneficial for patients that relapsed after previous infusions of CAR T cell therapies.” 

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.